Ropes & Gray represented Foghorn Therapeutics in its registered direct offering of 12,743,039 shares of common stock $5.51 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock for total gross proceeds of approximately $110 million. The closing was announced in a May 22 press release.
Foghorn is a Cambridge, Mass., biopharmaceutical company developing a novel class of oncology medicines that target genetically-determined dependencies within the chromatin regulatory system.
The Ropes & Gray team included capital markets partner Rachel Phillips, life sciences partner Marc Rubenstein, tax partner Eric Behl-Remijan, and life sciences regulatory & compliance partner Kellie Combs.
